Trials / Completed
CompletedNCT00206024
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
A 4-week Study to Investigate the Relationship Between Resolution of Acid-Associated Heartburn Symptoms and Dose of Esomeprazole Magnesium
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 330 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, double-blind, parallel-group, randomized, proof of concept trial to investigate the relationship between dose of esomeprazole magnesium and acid-associated heartburn symptoms during 4 weeks of treatment. The safety and tolerability of esomeprazole magnesium in doses up to 40 mg BID will also be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole magnesium (Nexium) |
Timeline
- Start date
- 2004-11-01
- Completion
- 2005-07-01
- First posted
- 2005-09-21
- Last updated
- 2010-11-19
Locations
27 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00206024. Inclusion in this directory is not an endorsement.